Date: 2014-05-13
Type of information: Private placement
Company: Pledpharma (Sweden)
Investors:
Amount: SEK 20,25 million (€2.2 million)
Funding type: private placement
Planned used: This right issue will be used to include more patients in Pledpharma\'s ongoing colorectal cancer study. This study investigates whether pre-treatment with PledPharma’s drug PledOx can reduce severe chemotherapy induced side-effects. Last month, the company has announced that all participating countries are actively recruiting patients to Part 2 of the PLIANT study. At present, 25 patients have been treated in addition to those already treated the first part of the study.
Others: * On May 13, 2014, Pledpharma announced that its rights issue with subscription period from 25 April – 9 May 2014 was oversubscribed by 82 percent. PledPharma receives approximately SEK 20,25 million (€2.2 million) before issue costs. The rights issue was subscribed to approximately 98,6 percent with preferential rights and the remaining 1,4 percent were subscribed for without preferential rights. The new share issue was, thus, fully subscribed. Shares subscribed for without preferential rights, will be allocated to shareholders who exercised subscription rights in relation to the number of existing subscription rights used by each shareholder. The rights issue will increase the number of shares by 1.687.314 to a total of 23 622 403 shares and the share capital will increase by SEK 88.806 to SEK 1.243 284.
Therapeutic area: Cancer - Oncology
